BMI and Contraceptives Affect New Age-, Sex-, and Puberty-adjusted IGF-I and IGFBP-3 Reference Ranges Across Life Span.

Abstract

CONTEXT:

Various clinical factors influencing serum levels of insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) are not entirely consistently described.

OBJECTIVE:

We asked whether body mass index (BMI), contraceptive drugs (CDs), and hormone replacement therapy (HRT) have potential effects on data for interpreting new age-, sex-, and puberty-adjusted reference ranges for IGF-I and IGFBP-3 serum levels.

DESIGN AND SETTING:

Subjects were mainly participants from 2 population-based cohort studies: the LIFE Child study of children and adolescents and the LIFE Adult study.

PARTICIPANTS:

We investigated 9400 serum samples from more than 7000 healthy and 1278 obese subjects between 3 months and 81 years old.

MAIN OUTCOME MEASURES:

Associations between IGF-I or IGFBP-3, measured with a new electrochemiluminescence immunoassay, and the predictors BMI and CDs were estimated using hierarchical linear modeling.

RESULTS:

During infancy, obese children had up to 1 SD score (SDS) higher mean predicted IGF-I values, converging with levels of normal-weight subjects up to 13 years old. Between 20 and 40 years of age, obesity was related to up to -0.5 lower IGF-I SDS values than the predicted values. Obesity had less impact on IGFBP-3. Estrogen- and progestin-based CDs, but not HRT, decreased IGF-I and increased IGFBP-3 (P < 0.01) in adolescents (β IGF-I = -0.45, β IGFBP-3  = 0.94) and adults (β IGF-I = -0.43, β IGFBP-3  = 1.12). Conversely, progestin-based CDs were significantly positive associated with IGF-I (β IGF-I  =0.82).

CONCLUSIONS:

BMI and CDs must be considered when assessing and interpreting the clinical relevance of IGF-I and IGFBP-3 measurements.

• Authors: Charlott Hörenz, Mandy Vogel, Kerstin Wirkner, Uta Ceglarek, Joachim Thiery, Roland Pfäffle, Wieland Kiess, Jürgen Kratzsch
• Journal: The Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 107 Issue 7 Pg. e2991-e3002 (06 16 2022) ISSN: 1945-7197 [Electronic] United States
• PMID: 35294528 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Contraceptive Agents
• Insulin-Like Growth Factor Binding Protein 3
• Progestins
• Insulin-Like Growth Factor I

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Body Mass Index
• Child
• Child, Preschool
• Contraceptive Agents
• Humans
• Infant
• Insulin-Like Growth Factor Binding Protein 3 (blood)
• Insulin-Like Growth Factor I (metabolism)
• Longevity
• Middle Aged
• Pediatric Obesity
• Progestins
• Puberty
• Reference Values
• Young Adult